vs
KINGSTONE COMPANIES, INC.（KINS）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
KINGSTONE COMPANIES, INC.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.6倍（$56.4M vs $35.5M），KINGSTONE COMPANIES, INC.净利率更高（26.2% vs -304.2%，领先330.4%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 34.0%），KINGSTONE COMPANIES, INC.自由现金流更多（$73.1M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 25.6%）
金斯顿公司总部位于纽约金斯顿，核心业务通过旗下金斯顿保险公司开展财产意外保险产品服务，同时旗下持纽约州牌照的保险保费融资公司Payments, Inc.，会与第三方持牌保费融资机构签订合作协议。在2010年专业保险代理人协会的企业绩效调查中，金斯顿保险公司在81家参评保险公司中排名第一。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
KINS vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $56.4M | $35.5M |
| 净利润 | $14.8M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 32.7% | -304.8% |
| 净利率 | 26.2% | -304.2% |
| 营收同比 | 34.0% | 681.7% |
| 净利润同比 | 171.4% | 39.6% |
| 每股收益（稀释后） | $1.09 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $56.4M | $35.5M | ||
| Q3 25 | $55.7M | $5.2M | ||
| Q2 25 | $52.3M | $19.2M | ||
| Q1 25 | $50.5M | $14.7M | ||
| Q4 24 | $42.1M | $4.5M | ||
| Q3 24 | $40.8M | $26.1M | ||
| Q2 24 | $36.5M | $14.4M | ||
| Q1 24 | $35.8M | $13.8M |
| Q4 25 | $14.8M | $-108.1M | ||
| Q3 25 | $10.9M | $-162.3M | ||
| Q2 25 | $11.3M | $-171.9M | ||
| Q1 25 | $3.9M | $-202.5M | ||
| Q4 24 | $5.4M | $-178.9M | ||
| Q3 24 | $7.0M | $-95.8M | ||
| Q2 24 | $4.5M | $-97.5M | ||
| Q1 24 | $1.4M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | 32.7% | -304.8% | ||
| Q3 25 | 24.6% | -3327.6% | ||
| Q2 25 | 27.1% | -916.8% | ||
| Q1 25 | 9.3% | -1297.9% | ||
| Q4 24 | 15.9% | -4042.4% | ||
| Q3 24 | 22.3% | -377.1% | ||
| Q2 24 | 15.7% | -697.4% | ||
| Q1 24 | 5.0% | -698.4% |
| Q4 25 | 26.2% | -304.2% | ||
| Q3 25 | 19.5% | -3135.3% | ||
| Q2 25 | 21.5% | -894.2% | ||
| Q1 25 | 7.7% | -1373.3% | ||
| Q4 24 | 12.9% | -3935.5% | ||
| Q3 24 | 17.1% | -367.5% | ||
| Q2 24 | 12.4% | -676.6% | ||
| Q1 24 | 4.0% | -662.4% |
| Q4 25 | $1.09 | $-0.17 | ||
| Q3 25 | $0.74 | $-0.36 | ||
| Q2 25 | $0.78 | $-0.41 | ||
| Q1 25 | $0.27 | $-0.50 | ||
| Q4 24 | $0.44 | $-0.56 | ||
| Q3 24 | $0.55 | $-0.34 | ||
| Q2 24 | $0.37 | $-0.40 | ||
| Q1 24 | $0.12 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | $4.4M | $9.6M |
| 股东权益账面价值 | $122.7M | $1.1B |
| 总资产 | $453.4M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.04× | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
| Q4 25 | $4.4M | $9.6M | ||
| Q3 25 | $4.8M | $11.9M | ||
| Q2 25 | $5.1M | $14.2M | ||
| Q1 25 | $5.4M | $16.4M | ||
| Q4 24 | $11.2M | $19.0M | ||
| Q3 24 | $17.3M | $20.5M | ||
| Q2 24 | $25.3M | $22.9M | ||
| Q1 24 | $25.3M | — |
| Q4 25 | $122.7M | $1.1B | ||
| Q3 25 | $107.7M | $1.0B | ||
| Q2 25 | $94.9M | $919.1M | ||
| Q1 25 | $82.2M | $933.9M | ||
| Q4 24 | $66.7M | $1.0B | ||
| Q3 24 | $59.7M | $524.6M | ||
| Q2 24 | $40.8M | $584.4M | ||
| Q1 24 | $35.7M | $401.2M |
| Q4 25 | $453.4M | $1.5B | ||
| Q3 25 | $428.6M | $1.4B | ||
| Q2 25 | $393.4M | $1.3B | ||
| Q1 25 | $385.4M | $1.3B | ||
| Q4 24 | $374.9M | $1.4B | ||
| Q3 24 | $347.0M | $726.5M | ||
| Q2 24 | $319.8M | $775.9M | ||
| Q1 24 | $318.3M | $557.8M |
| Q4 25 | 0.04× | 0.01× | ||
| Q3 25 | 0.04× | 0.01× | ||
| Q2 25 | 0.05× | 0.02× | ||
| Q1 25 | 0.07× | 0.02× | ||
| Q4 24 | 0.17× | 0.02× | ||
| Q3 24 | 0.29× | 0.04× | ||
| Q2 24 | 0.62× | 0.04× | ||
| Q1 24 | 0.71× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $75.9M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $73.1M | $-47.3M |
| 自由现金流率自由现金流/营收 | 129.5% | -133.1% |
| 资本支出强度资本支出/营收 | 5.0% | 3.5% |
| 现金转化率经营现金流/净利润 | 5.14× | — |
| 过去12个月自由现金流最近4个季度 | $124.0M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $75.9M | $-46.1M | ||
| Q3 25 | $25.9M | $-117.4M | ||
| Q2 25 | $9.3M | $-76.4M | ||
| Q1 25 | $17.9M | $-132.0M | ||
| Q4 24 | $57.9M | $-115.4M | ||
| Q3 24 | $21.7M | $-59.2M | ||
| Q2 24 | $7.1M | $-82.2M | ||
| Q1 24 | $6.1M | $-102.3M |
| Q4 25 | $73.1M | $-47.3M | ||
| Q3 25 | $25.3M | $-117.6M | ||
| Q2 25 | $8.7M | $-79.6M | ||
| Q1 25 | $17.0M | $-133.8M | ||
| Q4 24 | $55.6M | $-116.7M | ||
| Q3 24 | $21.0M | $-63.8M | ||
| Q2 24 | $6.6M | $-83.4M | ||
| Q1 24 | $5.6M | $-109.0M |
| Q4 25 | 129.5% | -133.1% | ||
| Q3 25 | 45.4% | -2272.5% | ||
| Q2 25 | 16.6% | -413.9% | ||
| Q1 25 | 33.7% | -907.4% | ||
| Q4 24 | 132.1% | -2567.7% | ||
| Q3 24 | 51.6% | -244.6% | ||
| Q2 24 | 18.1% | -578.5% | ||
| Q1 24 | 15.5% | -789.9% |
| Q4 25 | 5.0% | 3.5% | ||
| Q3 25 | 1.2% | 4.7% | ||
| Q2 25 | 1.1% | 16.4% | ||
| Q1 25 | 1.7% | 12.4% | ||
| Q4 24 | 5.6% | 28.6% | ||
| Q3 24 | 1.7% | 17.5% | ||
| Q2 24 | 1.4% | 8.2% | ||
| Q1 24 | 1.5% | 48.2% |
| Q4 25 | 5.14× | — | ||
| Q3 25 | 2.38× | — | ||
| Q2 25 | 0.82× | — | ||
| Q1 25 | 4.60× | — | ||
| Q4 24 | 10.65× | — | ||
| Q3 24 | 3.12× | — | ||
| Q2 24 | 1.58× | — | ||
| Q1 24 | 4.27× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
